ArticleEndocrine2025
Postvaccine early-onset (PoVEO) forms of Graves' disease after anti-SARS-CoV-2 vaccination are characterized by favourable long-term disease outcomes.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hypokalemic paralysis complicated by Takotsubo cardiomyopathy in an euthyroid elderly male with Graves' disease during methimazole dose reduction.Journal of geriatric cardiology : JGC · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn a previous cohort of patients with new-onset of Graves' Disease (GD) during 2021, a "postvaccine early-onset (PoVEO)" after anti-COVID-19 vaccination emerged as a new and frequent nosological entity occurring in approximately one third of patients. Similar cohorts have also been reported with GD after anti-COVID vaccines, but to date there are no available data on long-term clinical outcomes.
methodsThis is a single-center retrospective study evaluating the 24-month clinical course of patients with early-onset (<4 weeks) GD after anti-COVID vaccination (PoVEO) compared to non-PoVEO patients. Biochemical tests, therapies used and follow-up visits were scheduled according to current guidelines, clinicians' experience and patients' needs.
resultsAs previously described, 64 patients were observed in 2021 and 20 (31.2%) had PoVEO. Individuals with PoVEO were characterized by distinctive features such as older age, a higher prevalence of male sex, and a better initial biochemical response. Eleven individuals were followed at other Centers (2 with PoVEO and 9 without) and were lost to follow-up. During the two-year follow-up, of the 53 individuals, 7 (13%) underwent definitive surgical or radioactive-iodine therapy (3 PoVEO and 4 non-PoVEO p = 0.67), and 30 (57%) presented disease remission with medical therapy alone. Excluding those who underwent definitive treatments, remission with medical therapy alone was observed in 13/15 (87%) individuals with PoVEO form and 17/31 (55%) non-PoVEO (p = 0.048).
conclusionIn this retrospective study of a cohort of individuals with the PoVEO form of GD, we found a more favourable clinical course, likely linked to transience of the triggering events. Despite these findings, individuals presenting with GD after SARS-CoV-2 vaccination should undergo an active surveillance program with repeat thyroid function testing.
Indexed as
Identifiers
40856956What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.